Drug intelligence / Profile preview

AGX-392

Development stage: Unknown
Lead developer: AgonOx
Modality: Tumor-Infiltrating Lymphocytes (TILs) → Native Immune Cells → Adoptive Cell Transfer → Cell Therapies
Administration: Intravenous

Overview

AGX-392 is an investigational adoptive cell therapy based on enhanced tumour-infiltrating lymphocytes (TILs) that are CD103+, CD39+, and CD8+. It is being developed by AgonOx for the treatment of neoplasms (cancers). The therapy involves modulating the activity of integrin subunit alpha E (CD103), inhibiting ectonucleoside triphosphate diphosphohydrolase 1 (CD39), and modulating cluster of differentiation 8 (CD8) to enhance anti-tumor immune responses. As of March 2025, its highest development phase is Discovery.

Targets

ITGAE (Integrin subunit alpha E)CD8A (CD8 alpha/beta Coreceptor)ENTPD1 (Ectonucleoside triphosphate diphosphohydrolase 1)

Beyond the preview

Go deeper on AGX-392.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on AGX-392.

Explore the full profile